Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Trial of Trastuzumab Deruxtecan and Biology-Driven Selection of Neoadjuvant Treatment for HER2-positive Breast Cancer: ARIADNE

NCT05900206 is registered in ClinicalTrials.gov with Karolinska University Hospital as lead sponsor.

NCT NCT05900206
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05900206 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Trial of Trastuzumab Deruxtecan and Biology-Driven Selection of Neoadjuvant Treatment for HER2-positive Breast Cancer: ARIADNE
Lead sponsor
Karolinska University Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
October 26, 2023
Completion date
April 30, 2032
Enrollment
370 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer